Inmagene and Affibody have formed a strategic partnership to develop and commercialize IMG-020 (aka ABY-035), a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases. Inmagene will be responsible for commercialization in mainland China, Hong Kong, Taiwan, and Macau (Greater China), and South Korea, as well as development activities in the Asia Pacific region, excluding Japan. Affibody will retain global commercial rights outside of Greater China and South Korea. The partners will work together to enroll patients into global registrational trials to support Biologics License Applications (BLAs) in multiple indications worldwide.
Under the terms of the agreement, Affibody will receive a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in Inmagene’s commercialization territory. Additionally, Inmagene will share the global development costs of select clinical trials and be eligible to receive payments and royalties from Affibody relating to certain global development and commercialization milestones. Affibody will be responsible for the manufacturing and supply of IMG-020 for development and commercialization worldwide and is not precluded from additional collaboration and licensing agreements in territories not covered by this agreement.
Inmagene is seeking worldwide licensing, collaborating, and partnering opportunities in immunology-related therapeutic areas, with a focus in Asia. Our clinical development team has strong global experience and has special knowledge and resources in Asia. In addition to clinical stage drug candidates, leveraging cost-efficient development capabilities, we are interested in in-licensing pre-clinical stage drug candidates as well.